Mechanistically, it is identified that the PDGF‐PDGFRb‐PI3K axis is indispensable for Periostin+ myofibroblast generation from non‐bone marrow CD34+ cells in AAA, offering a new therapeutic target for patients with AAA at a high risk of rupture. Here, CD34 is linked to triple-A syndrome.